AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 16 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Directly fused dendritic cell-leukemia cell hybrids were the most effective promoters of antileukemia cytotoxic T lymphocyte (CTL) immune responses in vitro, compared with dendritic cells pulsed with tumor cell fragments or with whole tumor cell lysates.
"Dendritic cells (DC) have been successfully used in clinical pilot studies to induce tumor-specific immunity as well as clinical response in selected patients," commented Joanna Galea-Lauri and colleagues at the Rayne Institute in London. "However, DC-based immunotherapy remains a challenge and several parameters need to be examined in order to optimize the induction of antitumor immune responses."
The investigators evaluated the ability of DCs loaded with antigen by three different methods to induce a major histocompatibility complex (MHC) class I-restricted CTL response against leukemia cells. DCs were directly fused to leukemia cells or were pulsed with apoptotic leukemia cell particles or with lysed whole tumor cells. The in vitro studies were done using the U937 cell line and human acute myeloid leukemia blasts (AML).
The DC-leukemia cell hybrids generated the strongest MHC class I-restricted and antigen-specific CTL response, followed by the DCs pulsed with tumor cells fragments and then DCs pulsed with whole-cell lysates.
"The data presented here suggest that the method of antigen loading onto ...
Source: HighBeam Research, Method of loading antigen onto dendritic cells affects immune...